Efficacy and Safety of Kefir Whey Postbiotics - Trial NCT06230302
Access comprehensive clinical trial information for NCT06230302 through Pure Global AI's free database. This phase not specified trial is sponsored by Hanyang University and is currently Enrolling by invitation. The study focuses on Sarcopenia. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hanyang University
Timeline & Enrollment
N/A
Dec 26, 2023
Jul 31, 2024
Primary Outcome
Grip strength test for both hands,Dual energy xray absorptiometry
Summary
Research staff conduct screening tests only on applicants who provide written consent and
 select research subjects who meet the selection criteria. Study subjects will visit for the
 first time within 4 weeks from the screening visit to reexamine the suitability of the study
 subject selection/exclusion criteria and then be enrolled in the human application test. The
 participants will be randomly assigned to the kefir lactic acid bacteria-derived whey
 post-biotics group and the placebo group for the first time. Complete the baseline evaluation
 by the date of visit. Afterwards, the participants will consume whey postbiotics derived from
 kefir lactic acid bacteria and a placebo product twice a day, 3g per time, for 12 weeks, and
 visit the institution a total of four times to perform a grip strength test, DXA. This survey
 will be conducted at Hanyang University Hospital. Research staff may conduct follow-up
 observations of study subjects as needed after final consumption of the kefir lactic acid
 bacteria-derived whey postbiotic group and placebo products or after early termination.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06230302
Non-Device Trial